Biosimilar Adoption: Past Experiences and Future Opportunities

Biosimilar implementation provides valuable means to drive cost-effectiveness by delivering high quality biologics at a fraction of the cost. Biosimilar agents continue to capture the majority of the market share across several therapeutic areas with utilization expected to further increase, reaching a broader patient and provider mix. Join this discussion for considerations regarding the evaluation and optimization of biosimilar utilization and how to leverage value for your practice. There is no CE credit for this activity.

Tuesday, June 27
3 - 4 p.m. ET


Jorge Garcia

Jorge Garcia PharmD, MS, MHA, MBA, FACHE, Activity Chair
Assistant Vice President
University of Alberta & Hypertension Canada
Baptist Health
Miami, Florida

Shubha Bhat

Shubha Bhat PharmD, MS, FCCP, BCACP
Clinical Pharmacy Specialist – Gastroenterology
University of Alberta & Hypertension Canada
Cleveland Clinic
Cleveland, Ohio

Aimee Banks

Aimee Banks, PharmD, BCPS, MSCS, Moderator
Clinical Pharmacist
Vanderbilt University Medical Center
Nashville, Tennessee

Target Audience

The target audience includes pharmacists practicing in hospitals and health systems, especially pharmacists in decision-making roles, to assist in the implementation of biosimilars.

Learning Objectives

  • Summarize biosimilar definitions and key concepts.
  • Discuss barriers and best practices in the adoption of biosimilars.
  • Identify the role of pharmacists in biosimilar implementation.


  • 3 p.m. - Welcome and Introductions
    Aimee Banks, PharmD, BCPS, MSCS
  • 3:05 – 3:50 p.m. - Biosimilar Adoption: Past Experiences and Future Opportunities
    Jorge Garcia, PharmD, MS, MHA, MBA, FACHE, Shubha Bhat, PharmD, MS, FCCP, BCACP
  • 3:50  p.m. - Questions and Answers
    All Faculty


ASHP Advantage logo Provided by ASHP. Sponsored in part by Amgen. Supported in part by an independent medical education grant from Sandoz Inc., a Novartis Division. For questions and assistance to participate, contact us.